Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
Advertisement

Related Content

Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Shionogi In-licenses Shire ADHD Drugs In Untapped Japanese Market
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 1 of 2)
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 1 of 2)
Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan
Advertisement
UsernamePublicRestriction

Register

SC078793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel